Ernexa Therapeutics Inc.
ERNA
$2.45
-$0.18-6.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -99.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -99.79% | |||
| Cost of Revenue | -- | 100.00% | |||
| Gross Profit | -- | -99.82% | |||
| SG&A Expenses | -17.96% | -48.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.19% | -37.58% | |||
| Operating Income | -1.22% | 29.67% | |||
| Income Before Tax | -42.55% | 78.38% | |||
| Income Tax Expenses | -27.27% | -8.33% | |||
| Earnings from Continuing Operations | -42.42% | 78.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.42% | 78.35% | |||
| EBIT | -1.22% | 29.67% | |||
| EBITDA | -1.27% | 29.49% | |||
| EPS Basic | -2.26% | 96.94% | |||
| Normalized Basic EPS | 12.89% | 83.35% | |||
| EPS Diluted | -2.26% | 96.94% | |||
| Normalized Diluted EPS | 12.89% | 83.35% | |||
| Average Basic Shares Outstanding | 39.11% | 609.02% | |||
| Average Diluted Shares Outstanding | 39.11% | 609.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||